You have 9 free searches left this month | for more free features.

City

Shanghai (2)

Nanjing (1)

Condition

Gastric Cancer (1)

NSCLC (1)

Osteosarcoma (1)

Soft Tissue Sarcoma (1)

Overall Status

Recruiting (2)

Enrolling by invitation (1)

Sign in for free

Phase

early phase 1 (3)

Sponsor

Base Therapeutics (Shanghai) Co., Ltd. (3)

Collaborator

Shanghai 10th People's Hospital (1)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)

The General Hospital of Eastern Theater Command (1)

Intervention

nk510 (3)

tislelizumab,atezolizumab or sugemalimab (1)

tislelizumab,atezolizumab or trastuzumab (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (3)

nk510

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Osteosarcoma, Soft Tissue Sarcoma Trial in Shanghai (NK510)

Recruiting

Osteosarcoma
Soft Tissue Sarcoma

NK510

Shanghai, China

Shanghai General Hospital

Oct 31, 2023

Gastric Cancer Trial in Shanghai (NK510, Tislelizumab,atezolizumab or Trastuzumab)

Enrolling by invitation

Gastric Cancer

NK510
Tislelizumab，atezolizumab or Trastuzumab

Shanghai, China

Shanghai Tenth People's Hospital

Oct 22, 2023

NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

Recruiting

NSCLC

NK510
Tislelizumab，atezolizumab or sugemalimab

Nanjing, Jiangsu, China

General Hospital of Eastern Theater Command

Oct 23, 2023